Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMPHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ORMP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $181.78M
- P/E (TTM)
- 1.06
- EPS (TTM)
- $4.13
- Dividend yield
- 5.71% ($0.00)
- Ex-dividend date
- Jan 16, 2026
- 52-week range
- 2.09 – 5.47
- Day range
- 4.35 – 4.45
- Volume / Avg
- 84.73K / 194.48K
- Beta
- —
- Shares outstanding
- 41.60M
52-week range
ORMP stock today
Shares of Oramed Pharmaceuticals (ORMP) finished lower on Oct 7 at $4.37, a drop of 0.23% or $0.01 per share, versus the S&P 500's 0.22% decline. Trading was light, with 84.73K shares changing hands, about 44% of the average daily volume. At this level, ORMP sits in the middle of its 52-week range of $2.09 to $5.47: 20.1% below the high, set on Aug 27, 2026 and 109.1% above the low.
ORMP is up 53.3% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 76.2%. Oramed Pharmaceuticals trades at 1.1x its trailing twelve-month earnings per share of $4.13.
Summary generated from market data by MetaCap's automated system. Methodology
About Oramed Pharmaceuticals
Company profileOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Nadav Kidron Esq.
- Headquarters
- New York, NY
- Website
- oramed.com
Analyst forecast
ForecastConsensus
none
Avg. price target
$7.00+60.18%
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Dividends
Dividend history- Annual dividend
- $0.00
- Dividend yield
- 5.71%
- Last payment
- $0.25
- Ex-dividend date
- Jan 16, 2026
ORMP news
All ORMP newsOramed Pharmaceuticals peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ANTXAN2 Therapeutics Inc. | 4.85 | -4.34% | $183.02M | vs ORMP |
| CMPXCompass Therapeutics Inc. | 1.02 | +2.19% | $183.69M | vs ORMP |
| CNTNCanton Strategic Holdings Inc. | 2.26 | -3.42% | $180.08M | vs ORMP |
| NGENNervGen Pharma Corp. | 1.74 | -0.57% | $187.09M | vs ORMP |
| ADAGAdagene Inc. ADR | 2.81 | -4.10% | $188.67M | vs ORMP |
| YARWYarrow Bioscience Inc. | 18.78 | +0.24% | $174.69M | vs ORMP |
| DTILPrecision BioSciences Inc. | 6.25 | +0.81% | $172.51M | vs ORMP |
| WHWKWhitehawk Therapeutics Inc. | 3.41 | -5.54% | $194.40M | vs ORMP |
Indexes, lists and sector
Oramed Pharmaceuticals stock FAQ
What is Oramed Pharmaceuticals's stock price today?
ORMP last traded at $4.37 as of Oct 7, 4:00 PM EDT, down 0.23% on the day. Prices are delayed at least 15 minutes.
Does Oramed Pharmaceuticals pay a dividend?
Yes. Oramed Pharmaceuticals pays $0.00 per share annually, a 5.71% yield. The most recent dividend of $0.25 had an ex-dividend date of Jan 16, 2026.
What is ORMP's P/E ratio?
ORMP trades at a trailing P/E ratio of 1.06.
Who is Oramed Pharmaceuticals's CEO?
Mr. Nadav Kidron Esq. is the chief executive officer of Oramed Pharmaceuticals Inc..
Has ORMP ever split its stock?
Yes. The most recent ORMP stock split was a 1-for-12 split on Jan 23, 2013.
What is the ORMP 52-week high?
The 52-week high for ORMP is $5.47 and the 52-week low is $2.09. The stock is currently 20.1% below its high.